One More Step Toward Treatment of PARP Inhibitor-resistant Ovarian Cancers | Oncotarget



January 9, 2024

  • Share
  • Oncotarget published this trending editorial on December 22, 2023 in Volume 14, entitled, “One more step toward treatment of PARP inhibitor-resistant ovarian cancers” by researchers from the Department of Experimental Pathology and Medicine, Mayo Clinic School of Medicine and Science, Rochester, MN. DOI - Correspondence to - Viji Shridhar - Sign up for free Altmetric alerts about this article - Subscribe for free publication alerts from Oncotarget - Keywords - cancer, ovarian cancer, PARP inhibitors, PG545, DNA damage, cell death About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit and connect with us: SoundCloud - Facebook - X - Instagram - YouTube - LinkedIn - Pinterest - Reddit - Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

    Cancer ResearchCell ScienceDrug Discovery

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.